VBIO Valion Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1787740 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-49.6%
TTM net income YoY-16.9%
TTM EPS YoY—
Revenue 3-yr CAGR-35.8%
Net income 3-yr CAGR—
Margins
Gross margin-58.1%
Operating margin-1,210.8%
Net margin-1,557.3%
FCF margin-1,263.5%
EBITDA margin-1,210.4%
Returns
ROE-240.3%
ROA-156.0%
ROIC (approx.)-1,514.1%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets10.2%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-29.7%
Payout ratio—
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $780,000 | $1.18M | $1.84M | $1.26M |
| Cost of revenue | — | $778,000 | $889,000 | $1.54M | $1.29M |
| Gross profit | — | $2,000 | $287,000 | $299,000 | -$38,000 |
| R&D expense | $3.13M | $1.31M | $1.66M | $1.73M | $878,000 |
| SG&A expense | $4.77M | $3.16M | $4.75M | $5.88M | $2.93M |
| Operating income | -$7.90M | -$4.48M | -$8.24M | -$10.10M | -$5.63M |
| Interest expense | $146,000 | $0 | — | — | — |
| Pretax income | $8.90M | $5.70M | -$8.24M | -$10.10M | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$8.88M | -$5.66M | -$8.24M | -$10.10M | -$8.49M |
| EBITDA | -$7.89M | -$4.47M | -$8.24M | -$10.09M | -$5.62M |
| EPS (basic) | -7.84 | -19.68 | -176.80 | -104.32 | -2.43 |
| EPS (diluted) | — | -19.68 | -176.80 | -104.32 | -2.43 |
| Weighted avg. shares (diluted) | — | 287,370 | 46,650 | 96,778 | 3.49M |
| Banking | |||||
| Net interest income | — | $6,000 | $1,000 | $2,000 | -$1.82M |
| Balance sheet | |||||
| Cash & equivalents | $12.64M | $2.00M | $3.40M | $3.52M | $12.97M |
| Receivables | — | $69,000 | $174,000 | $107,000 | $92,000 |
| Inventory | $0 | $319,000 | $756,000 | $863,000 | $429,000 |
| Current assets | $13.01M | $2.64M | $4.65M | $5.31M | $14.29M |
| PP&E, net | $12.64M | $2,000 | $122,000 | $12,000 | $11,000 |
| Goodwill | $3.46M | $0 | — | — | — |
| Intangibles | $2.24M | $0 | — | — | — |
| Total assets | $31.61M | $2.81M | $5.16M | $5.88M | $15.04M |
| Current liabilities | $646,000 | $272,000 | $1.40M | $1.88M | $1.22M |
| Total liabilities | $7.44M | $272,000 | $1.58M | $2.25M | $1.76M |
| Shareholders' equity | $16.80M | $2.54M | $3.58M | $3.63M | $13.27M |
| Shares outstanding | 2.53M | 556,902 | 86,241 | 96,778 | 9.72M |
| Cash flow statement | |||||
| Operating cash flow | -$7.00M | -$5.72M | -$8.51M | -$8.92M | -$5.61M |
| Capital expenditure | $38,000 | $0 | $118,000 | $11,000 | — |
| Free cash flow | -$7.04M | -$5.72M | -$8.63M | -$8.93M | — |
| Investing cash flow | -$705,000 | $0 | -$118,000 | -$11,000 | — |
| Financing cash flow | $18.35M | $4.33M | $8.51M | -$528,000 | $17.54M |
| Depreciation & amortization | $5,000 | $3,000 | $8,000 | $10,000 | $8,000 |
| Stock-based compensation | $564,000 | $229,000 | $271,000 | $398,000 | $57,000 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.